Search

Displaying results 1651 - 1660 of 5449 in total
  1. Drug

    Nonoxynol-9

    go.drugbank.com/drugs/DB06804
    ApprovedWithdrawn

    It is the most commonly used spermicidal contraceptive in the UK and the USA. In several European countries, spermicides are no longer on the market.

    Products: OKSİNOL 150 MG OVÜL
  2. Drug

    Ferric carboxymaltose

    go.drugbank.com/drugs/DB08917
    ApprovedInvestigational

    It was FDA approved on July 25, 2013.

    Products: Ferinject® 50 mg iron/mL solution for injection/infusion, Ferapplic 500 mg/10 ml Enjeksiyonluk/İnfüzyonluk Çözelti, 1 flakon
  3. Drug

    Cefadroxil

    go.drugbank.com/drugs/DB01140
    ApprovedInvestigationalVet approvedWithdrawn

    Long-acting, broad-spectrum, water-soluble, cephalexin derivative.

    Products: HANACEF CAPSULE 500 mg, Biodroxil 500 mg - Kapseln
  4. Drug

    Amuvatinib

    go.drugbank.com/drugs/DB12742
    Investigational

    Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3.

  5. Drug

    Cobalamin

    go.drugbank.com/drugs/DB14098
    ApprovedInvestigational

    Mixtures: Folika-MG
  6. Drug

    Bezafibrate

    go.drugbank.com/drugs/DB01393
    ApprovedInvestigational

    It decreases low density lipoproteins and increases high density lipoproteins.

    Products: BEZAFIBRATO 200 MG, ZAFIBRAL TABLET 200 mg
  7. Drug

    Stannous fluoride

    go.drugbank.com/drugs/DB11092
    ApprovedInvestigational

    It is an FDA-approved over-the-counter product. … Although similar in function and activity to Sodium Fluoride (NaF), the conventionally added ingredient in toothpastes, stannous fluoride has been shown to be more effective at stopping and reversing dental

    Products: H E B Restore and Defend
  8. Drug

    Dordaviprone

    go.drugbank.com/drugs/DB14844
    ApprovedInvestigational

    [L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation. … activation of mitochondrial caseinolytic protease P (ClpP), antagonism of the dopamine D2 receptor,[L53833] activation of Activating Transcription Factor 4 (ATF4), and induction of endoplasmic reticulum (ER

    Synonyms: 7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo(1,2-A)pyrido(3,4-E)pyrimidin-5(4H)-one, 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimidin-5(1H)-one
  9. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [A187559] Adagrasib targets KRAS<sup>G12C</sup>, one of the most common KRAS mutations, at the cysteine 12 residue and inhibits KRAS-dependent signalling. … [L43847] In December 2022, the FDA granted accelerated approval to adagrasib for the treatment of KRAS<sup>G12C</sup>-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic

  10. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    [A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. … [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794]